

#### USA


WHO label	Lineage #	%Total	95%PI
Omicron	KP.3.1.1	42.2%	37.7-46.9%
	KP.2.3	14.6%	12.4-17.0%
	KP.3	14.2%	12.8-15.8%
	LB.1	13.5%	11.3-16.0%
	KP.2	3.1%	2.4-4.0%
	LP.1	3.1%	2.0-4.7%
	KP.1.1.3	2.6%	1.9-3.6%
	KP.1.1	2.0%	1.5-2.6%
	KS.1	1.0%	0.6-1.7%
	KP.2.15	0.8%	0.4-1.4%
	LF.3.1	0.7%	0.5-1.1%
	JN.1.16.1	0.7%	0.5-0.9%
	JN.1.18	0.5%	0.4-0.8%
	KP.4.1	0.3%	0.1-0.7%
	JN.1	0.2%	0.1-0.3%
	JN.1.11.1	0.2%	0.1-0.3%
	XDV.1	0.1%	0.0-0.2%
	KW.1.1	0.1%	0.0-0.2%
	JN.1.16	0.1%	0.0-0.1%
	KP.1.2	0.0%	0.0-0.1%
	JN.1.7	0.0%	0.0-0.1%
	KQ.1	0.0%	0.0-0.0%
	JN.1.13.1	0.0%	0.0-0.0%
	JN.1.4.3	0.0%	0.0-0.0%
	XDP	0.0%	0.0-0.0%
	JN.1.8.1	0.0%	0.0-0.0%


<sup>\*\*</sup> These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates
# Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one 2-week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during a
2-week periods displayed. While all lineages are tracked by CDC, those named lineages not enumerated in this graphic are aggregated with their parent lineages, based on Pango lineage definitions, describer in more detail here: https://web.archive.org/web/20240116214031/https://www.pango.network/the-pango-nomenclature-system/statement-of-nomenclature-rules.

Nowcast Estimates for 8/18/2024 – 8/31/2024 by HHS Region

# **COVID-19 Update for the United States**

### **Severity Indicators**







CDC | Test Positivity data through: August 31, 2024; Emergency Department Visit data through: August 31, 2024; Hospitalization data through: August 17, 2024; Death data through: August 31, 2024.

August 31, 2024.

# Percentage of Provisional Deaths Due to COVID-19 in the Past week, by State/Territory-United States





# Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025

## What is already known about this topic?

- The 2023–2024 COVID-19 vaccines provided protection against SARS-CoV-2 XBB-sublineage strains
- However, these strains are no longer predominant in the United States.

## What is added by this report?

• August 2024, the FDA approved and authorized the 2024–2025 COVID-19 vaccines by Moderna and Pfizer-BioNTech (Omicron KP.2 strain) and Novavax (Omicron JN.1 strain).

## What are the implications for public health practice?


• The 2024–2025 COVID-19 vaccines are recommended for all persons aged ≥6 months to provide additional protection against severe COVID-19—associated illness and death.

N Engl J Med, Volume 391(6):515-525, August 8, 2024

Postacute Sequelae of **SARS-CoV-2 Infection** in the Pre-Delta, Delta, and Omicron Eras


#### A Cumulative DALYs from 30 Days to 1 yr after Infection

No. at Risk



# Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras

N Engl J Med, Volume 391(6):515-525, August 8, 2024



In this study, the risk of postacute sequelae decreased over time but remained substantial even among vaccinated persons infected in the omicron era

# Cluster of Influenza A(H5) Cases Associated with Poultry Exposure at Two Facilities — Colorado, July 2024

# What is added by this report?

- The first known cluster of human influenza A(H5N1) cases in the United States associated with poultry exposure
- 109 (16.4%) of 663 workers performing poultry depopulation reported symptoms and received testing, and nine (8.3%) of the workers who received testing for influenza A(H5N1) received a positive result.
- All nine cases were associated with mild illness, with conjunctivitis as the most common symptom.

# Oropouche Virus Disease (OVD) Among U.S. Travelers — United States, 2024

## What is already known about this topic?

- Oropouche virus is an emerging arthropod-borne virus in the Americas.
- Reports of outbreaks in areas without previous endemic transmission, fatal cases, and vertical transmission with adverse pregnancy outcomes have raised concerns about human health risks.

## What is added by this report?

- As of August 16, 2024, 21 OVD cases among U.S. travelers returning from Cuba reported.
- Most patients had self-limited illness.

# Oropouche Virus Disease (OVD) Among U.S. Travelers — United States, 2024

- What are the implications for public health practice?
  - Clinicians and public health jurisdictions should be aware of the occurrence of OVD in U.S. travelers and request testing for suspected cases.
  - Travelers should prevent insect bites when traveling
  - Pregnant persons should consider deferring travel to areas experiencing outbreaks of OVD

